



2-22-01

GP-1644
Box Sequence

EXPRESS MAIL # EK102712465US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

Applicant: SOEGAARD, MORTEN, et al.

§
§
§
§
§
§
§
§
§

Docket No.: P01938US0

MAR 01 2001

Serial No.: 09/463,470

Examiner: VANDER VEGT

TECH CENTER 1600/2900

Filing Date: 01/21/2000

Art Unit: 1644

RECEIVED

Title: CYTOLYSIS OF TARGET CELLS
BY SUPERANTIGEN CONJUGATES
INDUCING T-CELL ACTIVATION

FEB 27 2001

TECH CENTER 1600/2900

Box Sequence Listing
Assistant Commissioner for Patents
Washington, D.C. 20231

TRANSMITTAL LETTER


Dear Sir:

Please find enclosed the following documents being filed in the above-referenced application:


- Sequence Transmittal Letter
- Sequence Listing
- Disk for Sequence Listing (2 copies)
- Copy of Notice to Comply with Sequence Listing
- Post Card

Applicant believes that there is no additional fee required to file this paper. If Applicant is in error, the Commissioner is hereby authorized to charge any required fees and/or credits by this paper and during the entire pendency of this application to Account No. 06-2375/10001907.

Respectfully submitted,


Melissa W. Acosta
Registration No. 45,872

Date: February 21, 2001
FULBRIGHT & JAWORSKI L.L.P.
1301 McKinney, Suite 5100
Houston, Texas 77010-3095
(713) 651-5407 (Telephone)
(713) 651-5246 (Facsimile)



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

MAR 01 2001

TECH CENTER 1600/2900

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | CLASS | CLASSIFICATION |
|-----------------|-------------|----------------------|-------|----------------|
| 09/463,470 | 01/21/00 | SOEGAARD | M | P01938US0 |

HM22/0124

FULBRIGHT & JAWORSKI
1301 MCKINNEY
SUITE 5100
HOUSTON TX 77010-3095

EXAMINER

VANDER VEGT, F

ART UNIT

PAPER NUMBER

1644

DATE MAILED:

01/24/01

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

PENDING

Received


JAN 30 2001

Docket:

Client:

Attorney:

P01938US0
PHARMACIA & UPJOHN
DLF



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
ADDRESS:
ASSISTANT COMMISSIONER FOR PATENTS
Washington, D.C. 20231

| | | | |
|-----------------|-------------|----------------------|------------------|
| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTY. DOCKET NO. |
|-----------------|-------------|----------------------|------------------|

| |
|----------|
| EXAMINER |
|----------|

| | |
|----------|--------------|
| ART UNIT | PAPER NUMBER |
|----------|--------------|

5

DATE MAILED:

Please find below and/or attached an Office communication concerning the above identified application.

Commissioner of Patents and Trademarks


This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). A computer readable form (CRF) of the sequence listing was submitted. However, the CRF could not be processed by the Scientific and Technical Information Center (STIC) for the reason(s) set forth on the attached CRF Diskette Problem Report.


Applicant is given ONE MONTH, or THIRTY DAYS, whichever is longer, from the mailing date of this letter within which to comply with the sequence rules, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). In no case may an applicant extend the period for reply beyond the SIX MONTH statutory period. Direct the reply to the undersigned. Applicant is requested to return a copy of the attached CRF Diskette Problem Report with the reply.

Conclusion

1. Any inquiry concerning this communication or earlier communications from the Examiner should be directed to F. Pierre VanderVegt, whose telephone number is (703)305-6997. The Examiner can normally be reached Tuesday through Friday (and odd-numbered Mondays on 2001 365-day calendar) from 7:00 am to 4:00 pm ET. A message may be left on the Examiner's voice mail service. If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Ms. Christina Chan can be reached at (703)308-3973. Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center 1600 receptionist, whose telephone number is (703)308-0196.

F. Pierre VanderVegt, Ph.D.
Patent Examiner
Art Unit 1644


F. PIERRE VANDERVEGT
PATENT EXAMINER



Application No.: 09/463470

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☒ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☒ 7. Other: THE PAPER COPY MUST BEAR CORRESPONDING CORRECTIONS

Applicant Must Provide:

- ☒ An ~~initial~~ or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An ~~initial~~ or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY